TAMs upregulate Gfi‐1 in tumor cells by TGF‐β secretion, which ultimately leads to reduced sensitivity of tumor cells to gemcitabine by inhibiting HMGB1 (high mobility group box 1) and CTGF (connective tissue growth factor) expression.195. This evidence concerns the gene HMGB1 and neoplasm.